Around the Practice: CAR T in R/R MM: Bridging Real-World Evidence and Clinical Practice

home / around-the-practice / around-the-practice-car-t-in-r-r-mm-bridging-real-world-evidence-and-clinical-practice

Panelists discuss the evolving role of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM), highlighting its transformative impact on patient outcomes across diverse real-world settings, the importance of individualized treatment decisions based on comparative efficacy and toxicity of available therapies, innovative approaches like bridging with bispecific antibodies, strategic sequencing with other B-cell maturation antigen–targeted agents, early integration in the treatment pathway, proactive management of neurotoxicity and infections, expanding access to high-risk populations, and the critical need for collaboration between specialized centers and community providers to optimize patient care and maximize durable responses.

Late-Line R/R: Treatment Landscape

EP. 1: Late-Line R/R: Treatment Landscape

Surbhi Sidana, MD;Doris Hansen, MD;Melissa Alsina, MD;Leyla O. Shune, MD
June 30th 2025

Panelists discuss the transformative impact of chimeric antigen receptor (CAR) T-cell therapy on treating relapsed/refractory multiple myeloma (R/R MM) in real-world settings, emphasizing improved patient outcomes, the expanding role of real-world evidence, and the nuanced decision-making required in selecting among newly approved, highly effective immunotherapies.

Outcomes and Factors for Consideration When Choosing Between CAR T Therapies

EP. 2: Outcomes and Factors for Consideration When Choosing Between CAR T Therapies

Surbhi Sidana, MD;Doris Hansen, MD;Melissa Alsina, MD;Leyla O. Shune, MD
June 30th 2025

Panelists discuss the real-world comparison of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) chimeric antigen receptor (CAR) T-cell therapies for multiple myeloma, highlighting cilta-cel’s superior efficacy but higher toxicity and emphasizing the importance of tailoring treatment decisions to individual patient factors such as disease stage, health status, and personal preferences.